Co-Founder

Prior to founding NeraCare, Friedrich worked as a management consultant (McKinsey & Company) and investment banker (Morgan Stanley). He holds an MSc in Management from the London School of Economics and an MPH in Epidemiology from Yale University.

Co-Founder

Prior to founding NeraCare, Daniel  worked as M&A investment banker (Evercore) and management consultant (Roland Berger). He holds an MSc in Management from the London School of Economics and a BSc in Engineering from TU Darmstadt. 

Chief Development Officer

Michael is a seasoned professional  in IVD Development, QM & Regulatory Affaris. Prior to joining NeraCare, he served as Vice President Development/QMR at BioNTech and build BioNTech Diagnostics from scratch. He holds a PhD in Biology.

Chief Operating Officer

With experience in operations at multiple startups, Younes spearheads clinical operations at NeraCare. He studied Computer Science & Management at TU Darmstadt and Finance at WHU.

Founding Investor & Managing Director

Matthias is a founding investor into NeraCare and  management director of the GmbH. He is a seasoned entrepreneur, investor and veteran of the oncology industry (ex-Amgen; previous exit to Alliance Boots / KKR).

Head of Admin & Finance

Barbora manages financial planning, reporting, and controls to support our clinical and commercial operations at NeraCare. She holds a Bachelor’s in Accounting & Corporate Finance from the University of Economics, Prague.

Head of Business Development

Jeff leads business development and scientific partnerships, drawing on his background in developmental biology and immunology. He earned his Ph.D. from Baylor College of Medicine and holds a B.S. from Illinois State University.

Executive Assistant

Laura manages operations, compliance, and business workflow across NeraCare, supporting executives with finance, legal, and administrative processes. She holds a B.S. in Biochemistry from the University of Texas at Austin.

Lab Director & Co-MD of Synvie

Anton is the lab director at NeraCare's lab in Munich. He was instrumental in the development and validation of the Immunoprint assay. He holds an MD and previously led MEDITEL (Brazil) and MTS Meditel (Germany)

Head of Patient Programs & Co-MD of Synvie

Petra is a managing director  of Synvie, where  programs for patients with rare chronic diseases. She holds a B.Sc. in Business Administration & Business Psychology from FOM University.

Medical Science Liason

Markus drives market development for our biomarker signature in risk stratification and prognosis assessment. He brings over two decades of experience in scientific affairs and marketing from roles at Thermo Fisher Scientific, Biotest, and Baxter. He holds a Ph.D. in Chemistry from Ludwig-Maximilians-Universität München.

Senior Medical Lab Technologist

Alicia is a Medical Laboratory Technologist in our research lab focused on improving melanoma diagnostics and therapy.  She holds an M.S. in Cell & Molecular Biology from FAU Erlangen‑Nürnberg.

Senior Medical Lab Technologist

Jacqueline is a Medical Laboratory Technologist in our research lab focused on improving melanoma diagnostics and therapy. She previously led laboratory operations at SOGZ in Munich and is pursuing a B.A. in Health Management at PFH Göttingen.

Pathologist

Anette is a dermatologist and board-certified demato-pathologist

Senior Clinical Research Associate

Petra is a Senior Clinical Research Associate, drawing on over three decades of experience in clinical research. Trained as a medical documentarian at Schule für Medizinische Dokumentation Gießen, she is experienced in medical devices, oncology, and ethics‑committee processes.

Chairman of the Board, Managing Director at MIG Fonds AG

A biologist by training, Matthias is an internationally renowned biotech investor and hold over 25 years of experience in healthcare and pharmaceutical strategy. He has been part of MIG Fonds AG since 2010.

Board Member, Professor at HS Albig

A molecular biologist by training, Peter worked as a Research Scientist at Max Planck Institute. Before becoming a professor at HS Albig, we was a life science investor with BayBG, focusing on digital health, deep tech, diagnostics and biotech ventures.

Board Member, CEO at Proteomedix AG

Helge is the CEO of Proteomedix AG which develops biomarker signatures for prostate cancer patients. She previously spent 18 years at Qiagen in R&D and commercial roles. She also serves on the board of epigenomics, tesa labtec and evorion biosciences.

Board Observer, Investment Manager at BayBG

Lukas is an investment manager at BayBG. He supports high-growth startups, focusing on software, robotics, and logistics. He holds an MBA from Shanghai Jiao Tong University and a Diploma in Industrial Engineering from the University of Applied Sciences Munich.